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Abstract
Background: Key role of angiogenesis in tumor growth and metastasis based on accumulating
evidence and recent progress of immunotherapy have led us to investigate vaccine therapy
targeting tumor angiogenesis.
Methods:  C57BL/6J mice were vaccinated with a syngeneic endothelial cell line Tpit/E by
subcutaneous injection once a week. Prior to ninth vaccination, the mice were challenged with B16/
F10 melanoma cells by subcutaneous inoculation on the back for the tumor growth model or by
tail venous injection for the lung metastasis model. Development of subcutaneous tumor and lung
metastasis was monitored by computed tomography scanning, which enabled accurate evaluation
with the minimized sacrifice of mice.
Results: Vaccination with Tpit/E cells inhibited subcutaneous tumor growth and appearance of
lung metastasis compared to control. Survival period was elongated in the Tpit/E vaccination in
both of the two models. We also obtained hybridomas secreting specific antibodies to Tpit/E cells
from a mouse vaccinated with the cells, indicating that specific immune response to the syngeneic
endothelial cells was elicited.
Conclusion: These results suggest that vaccination with an autologous endothelial cell line may be
effective against melanoma.
Background
Cancer immunotherapy has now gained importance as
therapeutics especially for cancers resistant to surgery,
chemotherapy or radiation therapy. Previously, we have
shown that melanoma patients vaccinated with tumor
lysate pulsed-dendritic cells elicited antibody response to
carbonic anhydrase II of which expression was specific to
tumor endothelial cells [1]. Angiogenesis has been shown
to play a key role in tumor growth and metastasis and new
molecules targeting tumor angiogenesis have been discov-
ered and coming into clinical use [2-5]. These findings
have led us to investigate cancer vaccine therapy targeting
tumor angiogenesis.
Efficacy of immunotherapy targeting known molecules
associated in tumor angiogenesis such as VEGF [6],
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VEGFR-2 [7-10], FGF-2 [11], FGFR-1 [12], endoglin [13],
Tie-2 [14], HP59 [15], survivin [16], matrix metalloprotei-
nase [17], integrin beta3 [18], vascular endothelial-cad-
herin [19], angiomotin [20], and angiopoietin-2 [21]
have been reported. Many other immunogenic antigens
associated in tumor angiogenesis remains to be explored
for the relevance as a target of immunotherapy.
Immunotherapy targeting tumor vasculature appears to
have advantages over conventional immunotherapy tar-
geting cancer cells, as it is assumed that failure of antigen-
presentation mechanism, decrease of antigenicity by fre-
quent mutation seen in cancer cells do not occur in vascu-
lar endothelial cells and that access of effectors is much
easier in targeting vascular endothelium. So far, several
reports have shown that tumor growth and metastasis
were inhibited by vaccination with whole endothelial
cells in mice [22-24]. Among these reports, a syngeneic
sinusoidal endothelial cell vaccine has been shown to be
effective in BALB/c mice [23]. In the present study, we
tested an immortalized syngeneic endothelial cell line
originated from C57BL mice as a vaccine for treatment of
melanoma. Advantages in use of a cell line are as follows:
proliferating cells in culture may share angiogenic anti-
gens with tumor vascular endothelial cells [25], and a cell
line is able to supply as many cells as necessary with ease.
Here, we demonstrated that vaccination with a syngeneic
endothelial cell line Tpit/E inhibited growth and metasta-
sis of B16/F10 melanoma. We also obtained hybridomas
secreting specific antibodies to Tpit/E cells from the vacci-
nated mouse to prove occurrence of the specific immune
response to the syngeneic endothelial cells.
Methods
Cell lines and culture
B16/F10 melanoma and SP-2 myeloma cell lines were
provided by Cell Resource Center for Biomedical Research
Institute of Development, Aging and Cancer Tohoku Uni-
versity (Sendai, Japan), and cultured in RPMI-1640 (Inv-
itrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS;
Thermo Trace Ltd, Melbourne, Australia), at 37°C in an
atmosphere of 95% air and 5% CO2. Tpit/E vascular
endothelial cell line derived from pituitary gland of tem-
perature sensitive T-antigen transgenic mouse was pro-
vided by RIKEN BRC Cell Bank (Tsukuba, Japan), and
cultured in HAMF12/DMEM (Invitrogen, Carlsbad, CA)
with 10% horse serum (Nichirei, Tokyo, Japan) and 2.5%
FBS, at 33°C.
Animal models
C57BL/6J mice of six to eight weeks were purchased from
Tokyo Laboratory Animals Science (Tokyo, Japan). For the
subcutaneous tumor model, mice were inoculated with 1
× 105 melanoma cells suspended in 100 μl 50% Matrigel
(BD Biosciences, Bedford, MA)/phosphate buffered saline
(PBS) on the back. For the lung metastasis model, 1 × 105
melanoma cells suspended in 100 μl saline were injected
in the tail vein. All studies involving mice were approved
by the institute's Animal Study Committee.
Vaccination with fixed cells
Cultured cells in a sub-confluence condition were har-
vested and fixed in 0.025% glutaraldehyde/PBS for 20
min at room temperature (RT), followed by washing with
PBS for three times as described in a previous paper [23].
Vaccination was performed by inoculating 5 × 106 cells
subcutaneously once a week for 8 times before tumor
challenge and additional 4 times afterward (Fig. 1). For
control, PBS was injected subcutaneously.
Computed Tomography Scanning
Mice were anesthetized by intrapenetorial injection of 1
mg ketamine hydrochloride and 6.7 μg medetomidine
hydrochloride per mouse and subjected to computed
tomography scanning using LaTheta LCT-100A in-vivo CT
scanner for small animals (Aloka, Tokyo, Japan). For the
subcutaneous tumor model, cross-sectional CT scans were
taken at 1 mm intervals. Tumor volume was calculated by
integration of tumor area in each slice through the tumor
by the attached software. For the lung metastasis model,
cross-sectional CT scans were taken at 0.5 mm intervals
for the whole lung.
Hybridoma preparation
Fusion of spleen cells harvested from a sacrificed mouse
and myeloma cells was performed using Polyethylene
Glycol 1500 (Roche, Penzberg, Germany) based on the
manufacturer's instruction. Cells were cultured in S-Clone
medium (Sanko Junyaku, Tokyo, Japan) supplemented
with HAT-media supplement (Sigma-Aldrich Japan,
Tokyo, Japan). Selected cell colonies were isolated and
conditioned media were harvested and stored at -20°C
until use.
Experimental plan for vaccination and tumor challenge Figure 1
Experimental plan for vaccination and tumor chal-
lenge. Vaccination was performed once a week for 12 times. 
Tumor was challenged prior to ninth vaccination on the same 
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Immunofluorescence of cultured cells
Cultured Tpit/E and B16/F10 cells were fixed with metha-
nol, treated with 0.2% TritonX-100/PBS, washed with
PBS, treated with 1% bovine serum albumin (BSA)/PBS,
washed with PBS, and treated with the hybridoma-condi-
tioned medium for 30 min at RT. After washing with 0.1%
TritonX-100/PBS, 10 μg/mL fluorescein conjugated goat
anti-mouse IgG (Chemicon International, MA) diluted in
1% BSA, 0.1% TritonX-100/PBS was applied. After wash-
ing with 0.1% TritonX-100/PBS for 3 times, cells were
observed by fluorescence and phase contrast microscope.
For positive media, immunostaining was repeated after
blocking with 100 × diluted normal mouse serum in PBS
for 30 min at RT to rule out the possibility of non-specific
stickiness to endothelial cell surface molecules including
IgG Fc receptors [26].
Statistical analysis
Correlation between two factors, difference between two
groups and difference between survivals of two groups
were evaluated by the chi-square analysis, the t-test and
the Kaplan-Meier analysis respectively. P values less than
0.05 were considered statistically significant.
Results
Inhibition of subcutaneous tumor growth by the Tpit/E 
vaccination
B16/F10 cells were inoculated subcutaneously on the
back prior to ninth Tpit/E cell vaccination on the same
day and tumor growth was followed by CT scanning twice
a week. Experiments ware performed twice and one repre-
sentative experiment was shown. As shown in Fig. 2A,
tumor growth was significantly inhibited in the Tpit/E cell
vaccination group compared to control at day 14 and 17
after tumor challenge. Fig. 2B shows a time course of
tumor growth in each mouse. Decrease in tumor volume
due to massive necrosis in the course was observed in two
mice vaccinated with Tpit/E cells. Series of CT images in
time course of representative mice from each group are
shown in Fig. 2C. Subcutaneous tumor growth of control
mice was rapid, while tumors of the Tpit/E vaccinated
mice grew slowly with occasional tumor necrosis. Survival
period of the Tpit/E vaccination group was significantly
longer than control by Kaplan-Meier analysis (Fig. 2D).
Inhibition of lung metastasis by the Tpit/E vaccination
B16/F10 cells were injected into the tail vein on the same
schedule as the subcutaneous tumor model and develop-
ment of lung metastasis was followed by CT scanning. At
day 7 after tumor challenge, no metastasis was detected in
all mice. At day 14, metastases appeared in all of control
mice and three out of eight Tpit/E vaccination mice (Table
1). Metastasis appearance rate at this time point was sig-
nificantly inhibited by Tpit/E cell vaccination. Series of CT
images at day 14 and 21 post tumor challenge of repre-
sentative mice of each group are shown in Fig. 3A. Survival
period of the Tpit/E cell vaccination group was signifi-
cantly longer than control (Fig. 3B).
Tumor growth and survival rate in the subcutaneous tumor  model Figure 2
Tumor growth and survival rate in the subcutaneous 
tumor model. A. Subcutaneous tumor volume on the back 
at day 14 and 17 post tumor challenge. *: p < 0.01 (n = 4). 
Tumor volume was calculated by integration of consecutive 
cross-sections obtained by CT scans. B. Time course of sub-
cutaneous tumor volume of each mouse from tumor chal-
lenge until death. Tumor growth was apparently inhibited by 
Tpit/E vaccination. C. Series of CT scan images showing 
growth of the subcutaneous tumor. (a-d): a control mouse; 
day 10 (a), 14 (b), 17 (c) and 21 (d) after tumor challenge, (e-
h): a Tpit/E vaccinated mouse; day 10 (e), 21 (f), 24 (g) and 28 
(h) after tumor challenge. Tumors were indicated by arrow-
heads. Arrows in panel g. and h. point to necrotic region in 
the tumor. D. Survival rate after tumor challenge; p < 0.05: 
Tpit/E vaccine vs. control.
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Table 1: Animals with lung metastases at day 14 post tumor 
challenge
mice with metastasis mice without metastasis
control 6 0
T-pit/E vaccine 3 5
Animals with lung metastases at day 14 post tumor challenge; p < 
0.05: control vs. T-pit/E vaccine by the chi-square analysis.Journal of Experimental & Clinical Cancer Research 2009, 28:13 http://www.jeccr.com/content/28/1/13
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Anti-endothelial cell specific antibody generated in a Tpit/
E vaccinated mouse
To make sure that specific antibodies to Tpit/E cells are
generated in a mouse vaccinated with Tpit/E cells, we
aimed to obtain Tpit/E specific antibody-secreting hybrid-
oma clones. A surviving mouse in the Tpit/E cell vaccina-
tion group of the subcutaneous tumor model was
sacrificed at day 45 after tumor challenge. Hybridomas of
the spleen cells and SP-2 cells were prepared and the con-
ditioned media were subjected to immunostaining to
check the presence of IgG reactive to Tpit/E or B16/F10
cells. Some hybridoma clones were shown to secret anti-
bodies reactive to Tpit/E but not to B16/F10 cells. Images
of immunostaining with the medium of a representative
clone along with phase contrast images are shown (Fig.
4). Edge of the colonies of Tpit/E cells was strongly
stained, while B16/F10 cells were not stained.
Discussion
So far, vaccination with endothelial cells has been shown
to be effective in several mice models using xenogeneic
endothelial cells [22,24] and syngeneic endothelial cells
[23]. When considering therapeutic application to
human, autologous cells may be preferable to avoid host
reactions to allogeneic or xenogeneic components in the
vaccine. In addition, autologous cell vaccine may have
less possibility to induce pathologic autoimmunity due to
the tolerance mechanism. However, preparation of a con-
siderable amount of tumor vascular endothelial cells from
an individual patient is almost impossible. Therefore, we
tested the efficacy of a syngeneic endothelial cell line as a
substitute. In addition, cell lines are expected to share
characteristics with tumor vascular endothelial cells [25].
These advantages may have contributed to anti-tumor
effects on melanoma with high malignancy.
As for cancer models in the previous reports, employed
were fibrosarcoma, hepatoma, mammary carcinoma [22],
lung carcinoma [22,24], myeloma [24], and colon carci-
noma [23]. It is noteworthy that our study showed for the
first time the anti-tumor effect of an endothelial cell vac-
cine against B16/F10 melanoma in both of the subcutane-
ous tumor and the lung metastasis models. In the course
of the subcutaneous tumor growth, occasional tumor
necrosis in the Tpit/E vaccinated mice was observed, sug-
gesting occurrence of vascular damage, though further
studies are required. Once B16/F10 tumor was chal-
lenged, the tumor grew so rapidly and life span was within
several weeks without therapy in the present study. Con-
sidering a time length required for immune response after
vaccination, the anti-tumor effect seemed difficult to
detect in a therapeutic setting such as vaccination after
tumor challenge. However, anti-tumor effect in a thera-
Tumor growth and survival rate in the lung metastasis model Figure 3
Tumor growth and survival rate in the lung metasta-
sis model. A. Series of CT scan images showing develop-
ment of the lung metastases, (a, b): a control mouse, (c, d): a 
Tpit/E vaccinated mouse; day 14 (a, c) and 21 (b, d) after 
tumor challenge. Tumors were indicated by arrowheads. No 
lung metastasis was observed in panel c. B. Survival rate after 
tumor challenge, p < 0.05: Tpit/E vaccine vs. control.
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Antibody to Tpit/E cells generated in the vaccinated mouse Figure 4
Antibody to Tpit/E cells generated in the vaccinated 
mouse. Immunofluorescence (a, b) and corresponding phase 
contrast microscopic images (c, d) of cultured cells stained 
with a representative hybridoma-conditioned media, (a, c): 
B16/F10 cells, (b, d): Tpit/E cells. Hybridomas were produced 
from spleen cells of a Tpit/E-vaccinated mouse. The rim of 
Tpit/E cells was strongly stained, while B16/F10 was not, sug-
gesting that the hybridoma secreted specific IgG reactive to 
the surface of Tpit/E cells.Journal of Experimental & Clinical Cancer Research 2009, 28:13 http://www.jeccr.com/content/28/1/13
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peutic setting may be observed if challenged melanoma
cells are reduced.
In this study, we aimed to prove that specific antibodies to
Tpit/E cells were generated in the vaccinated mice. We
thought that positive immunostaining of Tpit/E cells with
sera of vaccinated mice may be insufficient because such
sera may contain a variety of antibodies including ones
against inoculated B16/F10 cells. Therefore, we isolated
antibodies by making hybridomas and obtained some
clones secreting antibodies reactive with Tpit/E but not
with B16/F10 cells. It is obvious that tumor endothelium
expresses specific molecules which are not expressed on
normal vascular endothelium [27]. Vaccination with Tpit/
E cells may have targeted such antigens because vaccina-
tion with autologous molecules might not provoke effec-
tive immune reaction due to the tolerance. Xenogeneic
cells or molecules have been widely employed as vaccines
because they tend to break the tolerance
[6,10,12,14,17,18,22,24,28]. To show that tumor
endothelium specific molecules are targeted, we plan to
identify antigen molecules recognized by isolated anti-
bodies in the present study by a proteomics strategy [1]. In
addition, effects of the isolated antibodies on tumor vas-
culature including antibody-dependent cytotoxic activity
and also the role of cellular immunity in the response to
vaccination should be explored as CTL activities to vacci-
nated endothelial cells in other settings have been shown
[23,24].
To apply the vaccine therapy using an autologous
endothelial cell line to human, development of the cell
line from a patient is a next subject. Practically, culture of
umbilical vein endothelial cells (HUVECs) on a close
genetic background may be a good candidate. Recently, a
pilot study of HUVECs vaccine in cancer patients with
promising results in brain tumors but not in colorectal
cancer was reported [29]. No prominent adverse effect
observed in the study may facilitate wider application of
HUVECs vaccine to various cancers including melanoma.
However, some tumor endothelium specific antigens are
reported to appear in the vasculature of wound healing
tissue [27], possible adverse effects of endothelial cell vac-
cine on wound healing remains to be clarified.
Conclusion
Vaccination with a syngeneic endothelial cell line Tpit/E
inhibited subcutaneous tumor growth as well as appear-
ance of lung metastasis and elongated survival period of
C57BL mice challenged with B16/F10 melanoma, and
elicitation of specific antibodies to Tpit/E cells was dem-
onstrated.
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